Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Phase 2 Terminated 30 enrolled UNC Lineberger Comprehensive Cancer Center Celgene Corporation · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and Abraxane.

Timeline

Start: 2006-04
Primary completion: 2010-07
Completion: 2014-12

Outcome

Outcome not reported

Stopped (Enrollment): “slow accrual”

Publications

Grilley-Olson JE, Keedy VL, Sandler A, Moore DT, Socinski MA, Stinchcombe TE. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist. 2015 Feb;20(2):105-6. doi: 10.1634/theoncologist.2014-0327. Epub 2015 Jan 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	6 unknown	Intravenous
Subject	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	240 mg/m2	Intravenous